Natco Pharma Limited
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.
What Natco files
- Others62
- Investor Meet41
- Updates27
- Dividend/Bonus10
- Board Meeting9
- PPTs7
NATCO Pharma's FY26 global revenue reached ₹4,375.9 Cr, a slight dip from FY25, with Q1FY27 revenue at ₹794.4 Cr, reflecting a high base effect from Q1FY26. Despite this, the company demonstrates strong long-term growth, achieving an 8% revenue CAGR over the past decade. Export formulations continue to drive sales, contributing...
NATCO Pharma reported solid Q3 FY26, with consolidated revenue hitting ₹705.4 Cr, up from ₹651.1 Cr last year. Net profit also climbed to ₹151.3 Cr from ₹132.4 Cr. Export formulations were the main driver, contributing 75.7% of total revenue. EPS for the quarter stood at ₹8.46, with EBITDA reaching ₹216.8...
Here's a summary of the Q1FY26 earnings presentation: **1. Financial Highlights:** Q1FY26 total revenue INR 1,390.6 Cr, profit after tax INR 480.3 Cr, with 45.5% EBITDA margin and EPS of INR 26.84. Net cash INR 3,474.0 Cr. **2. Strategic Initiatives & Growth Drivers:** NATCO expands its US pipeline with over...
Here is the summary based on your preferences: **Financial Highlights:** NATCO Pharma proposes a ₹ 2,000 Cr investment for a 35.75% stake in South Africa’s Adcock Ingram. Adcock reported FY24 revenue of US$ 536 Mn, with 15% EBITDA and 8% net profit margins. NATCO will consolidate its proportionate share of...
1. Financial Highlights: Total revenue for Q4FY25 stood at INR 1,287.3 Cr with pharma export formulations contributing INR 1,052.5 Cr and domestic formulations at INR 99.4 Cr. FY25 revenue reached INR 4,784 Cr, driven by INR 3,760 Cr from exports and INR 400 Cr from domestic formulations. EBITDA for Q4...